Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tachyon Therapeutics, Inc.

Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Conference
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Announces Presentation at the 2021 ESMO Annual Meeting
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
From Tachyon Therapeutics, Inc.
Via Business Wire
Tickers ABCL
Tachyon Announces Presentations at the ASCO Annual Meeting
From Tachyon Therapeutics, Inc.
Via Business Wire
Tachyon Presents Promising Preclinical Data on Its First-in-class Pan-KDM4 Epigenetic Regulator, TACH101
From Tachyon Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.